Loading…
UTI - Pharma & Healthcare Fund
Disclosed for 41 months, Jan 2014 to Jun 2017. This scheme is no longer reporting.
Portfolio value
₹307 Cr
up ₹1.1 Cr vs Feb 2016
- Stocks held
- 26
- up 1 vs Feb 2016
- Top 10 weight
- 72.1%
- of the portfolio in its ten largest
- Cash & debt
UTI - Pharma & Healthcare Fund is an active equity fund in the Sectoral / Thematic category from UTI Mutual Fund. In March 2016 it disclosed 26 stocks worth ₹307 Cr, up ₹1.1 Cr from Feb 2016. Its largest positions were Sun Pharmaceutical Industries Limited (23.0%), Dr. Reddy's Laboratories Limited (11.5%), Lupin Limited (9.4%); the ten largest together made up 72.1% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 87.1% of its equity. Cash and debt stood at 7.9%. Compared with Feb 2016 the fund entered 1 new stock and exited 0.
Against 230 other Sectoral / Thematic funds
Concentration
94%
Top-10 weight is higher than 94% of peers
Breadth
10%
Holds more stocks than 10% of peers
Cash
87%
Holds more cash than 87% of peers
What these mean: concentration · cash
Holdings in March 2016
Download CSVEvery line the fund disclosed, with the change against Feb 2016. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 23.04% | down 0.51 pts | ₹70.7 Cr | down ₹1.3 Cr | Trimmed |
| Dr. Reddy's Laboratories Limited | 11.54% | up 1.97 pts | ₹35.4 Cr | up ₹6.1 Cr | Added |
| Lupin Limited | 9.37% | down 1.78 pts | ₹28.8 Cr | down ₹5.4 Cr | Trimmed |
| Cipla Limited | 8.44% | up 1.00 pts | ₹25.9 Cr | up ₹3.2 Cr | Added |
| Cash, TREPS & receivables | 7.92% | down 3.76 pts | ₹24.3 Cr | down ₹11.4 Cr | Trimmed |
| Divi's Laboratories Limited | 4.17% | up 0.14 pts | ₹12.8 Cr | up ₹48 L | Added |
| Aurobindo Pharma Limited | 3.68% | up 0.43 pts | ₹11.3 Cr | up ₹1.4 Cr | Added |
| Alkem Laboratories Limited | 3.25% | up 0.95 pts | ₹10 Cr | up ₹3 Cr | Added |
| Piramal Enterprises Limited | 2.94% | up 0.36 pts | ₹9 Cr | up ₹1.1 Cr | Added |
| Biocon Limited | 2.86% | up 0.07 pts | ₹8.8 Cr | up ₹25 L | Added |
| IPCA Laboratories Limited | 2.77% | up 0.07 pts | ₹8.5 Cr | up ₹25 L | Added |
| Narayana Hrudayalaya Limited | 2.35% | up 0.04 pts | ₹7.2 Cr | up ₹16 L | Added |
| Zydus Lifesciences Limited | 2.22% | up 0.01 pts | ₹6.8 Cr | up ₹5 L | Added |
| Sun Pharma Advanced Research Company Limited | 2.18% | up 0.21 pts | ₹6.7 Cr | up ₹67 L | Added |
| Strides Pharma Science Limited | 1.96% | up 0.36 pts | ₹6 Cr | up ₹1.1 Cr | Added |
| Pfizer Limited | 1.69% | down 0.05 pts | ₹5.2 Cr | down ₹14 L | Trimmed |
| GlaxoSmithKline Pharmaceuticals Limited | 1.59% | up 0.27 pts | ₹4.9 Cr | up ₹84 L | Added |
| Sanofi India Limited | 1.53% | down 0.12 pts | ₹4.7 Cr | down ₹36 L | Trimmed |
| Unichem Laboratories Limited | 1.26% | up 0.13 pts | ₹3.9 Cr | up ₹40 L | Added |
| Syngene International Limited | 1.24% | down 0.04 pts | ₹3.8 Cr | down ₹10 L | Trimmed |
| Indraprastha Medical Corporation Limited | 1.06% | up 0.08 pts | ₹3.3 Cr | up ₹27 L | Added |
| Natco Pharma Limited | 0.82% | down 0.01 pts | ₹2.5 Cr | down ₹2 L | Trimmed |
| DISHMAN PHARMACEUTICALS & CHEMICALS LTD. | 0.66% | up 0.07 pts | ₹2 Cr | up ₹22 L | Added |
| Torrent Pharmaceuticals Limited | 0.62% | up 0.03 pts | ₹1.9 Cr | up ₹11 L | Added |
| Indoco Remedies Limited | 0.42% | up 0.03 pts | ₹1.3 Cr | up ₹9 L | Added |
| Shilpa Medicare Limited | 0.41% | up 0.03 pts | ₹1.3 Cr | up ₹9 L | Added |
| EQ-PP SUN PHARMA ADVANCED RESEARCH CO LTD. | 0.01% | up 0.01 pts | ₹4 L | up ₹4 L | New |
What changed, Feb 2016 to Mar 2016
New New positions (1)
- EQ-PP SUN PHARMA ADVANCED RESEARCH CO LTD.<0.1% · ₹4 L
Exited Exited (0)
None.
Added Biggest additions
- Dr. Reddy's Laboratories Limitedup ₹6.1 Cr (+1.97% pts)
- Cipla Limitedup ₹3.2 Cr (+1.00% pts)
- Alkem Laboratories Limitedup ₹3 Cr (+0.95% pts)
- Aurobindo Pharma Limitedup ₹1.4 Cr (+0.43% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Feb 2016, the weight rose most in Pharmaceuticals (+0.5 pts) and Finance (+0.3 pts), and fell most in Pharmaceuticals & Biotechnology (−0.6 pts) and Healthcare Services (−0.1 pts).
- Pharmaceuticals4.2% → 4.7%+0.5 pts
- Finance2.9% → 3.2%+0.3 pts
- Pharmaceuticals & Biotechnology87.7% → 87.1%−0.6 pts
- Healthcare Services5.2% → 5.0%−0.1 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Mar 2015 | Sep 2015 | Dec 2015 | Feb 2016 | Mar 2016 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 86.9% | 91.7% | 88.6% | 87.7% | 87.1% |
| Healthcare Services | — | 1.1% | 2.9% | 5.2% | 5.0% |
| Pharmaceuticals | 12.2% | 5.6% | 5.4% | 4.2% | 4.7% |
| Finance | 1.0% | 1.7% | 3.1% | 2.9% | 3.2% |
Allocation in Mar 2016change vs Feb 2016
- Pharmaceuticals & Biotechnology (17)87.1%▼ 0.6 pts
- Healthcare Services (3)5.0%▼ 0.1 pts
- Pharmaceuticals (5)4.7%▲ 0.5 pts
- Finance (1)3.2%
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Mar 2016
7.9%
▼ 3.8 pts vs Feb 2016
- Cash alone
- 7.9%
- cash and net receivables
- A year earlier
- 5.3%
- Mar 2015 · now ▲ 2.6 pts
- Last 12 months
- 5.9% – 12.6%
- lowest to highest · record 12.6% in Nov 2015
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.